NZ611898A - Compounds for inhibiting mitotic progression - Google Patents

Compounds for inhibiting mitotic progression

Info

Publication number
NZ611898A
NZ611898A NZ611898A NZ61189807A NZ611898A NZ 611898 A NZ611898 A NZ 611898A NZ 611898 A NZ611898 A NZ 611898A NZ 61189807 A NZ61189807 A NZ 61189807A NZ 611898 A NZ611898 A NZ 611898A
Authority
NZ
New Zealand
Prior art keywords
compounds
compound
formula
mitotic progression
inhibiting mitotic
Prior art date
Application number
NZ611898A
Other languages
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ611898(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ611898A publication Critical patent/NZ611898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ611898A 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression NZ611898A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
NZ597252A NZ597252A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
NZ611898A true NZ611898A (en) 2015-01-30

Family

ID=39315133

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ611898A NZ611898A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
NZ597252A NZ597252A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
NZ577042A NZ577042A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ597252A NZ597252A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression
NZ577042A NZ577042A (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2086981B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101110458B1 (enExample)
CN (2) CN103483343B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2537451T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX2009004670A (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ611898A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2086981T3 (enExample)
PT (2) PT2497772E (enExample)
RS (2) RS53788B1 (enExample)
SG (2) SG10201503350TA (enExample)
SI (2) SI2086981T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE381566T1 (de) 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
TW201026703A (en) * 2008-12-05 2010-07-16 Millennium Pharm Inc Thiolactams and uses thereof
ES2468391T3 (es) * 2008-12-22 2014-06-16 Millennium Pharmaceuticals, Inc. Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) * 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2526671T3 (es) * 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
EP3347350A1 (en) 2015-09-09 2018-07-18 Icahn School of Medicine at Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4504710A1 (en) 2022-04-07 2025-02-12 Eli Lilly and Company Process for making a kras g12c inhibitor
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
EP4547251A1 (en) 2022-06-30 2025-05-07 Eli Lilly and Company Kras g12c inhibitor for treating cancer
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ330973A (en) * 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
IL135303A0 (en) * 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU1651201A (en) 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
EP1345925B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
HK1134672A1 (en) 2010-05-07
ATE556076T1 (de) 2012-05-15
KR20110113210A (ko) 2011-10-14
PL2497772T3 (pl) 2015-05-29
TWI401255B (zh) 2013-07-11
DK2497772T3 (en) 2015-01-19
SI2086981T1 (sl) 2012-12-31
US20150166545A1 (en) 2015-06-18
CR10782A (es) 2009-06-24
US20210214361A1 (en) 2021-07-15
AU2007322046B2 (en) 2012-04-05
EP2944639A1 (en) 2015-11-18
PH12012502057B1 (en) 2018-10-24
NO20091864L (no) 2009-06-15
US8026246B2 (en) 2011-09-27
CN101547924A (zh) 2009-09-30
NZ577042A (en) 2012-03-30
EA015779B1 (ru) 2011-12-30
RS53788B1 (sr) 2015-06-30
BRPI0718803B8 (pt) 2021-05-25
CA2669680C (en) 2012-04-10
CL2007003244A1 (es) 2008-04-04
MX343391B (es) 2016-11-04
NZ597252A (en) 2013-06-28
EP2497772A1 (en) 2012-09-12
CA2669680A1 (en) 2008-05-29
US11958855B2 (en) 2024-04-16
BRPI0718803A2 (pt) 2013-12-03
HK1217699A1 (en) 2017-01-20
TW200829589A (en) 2008-07-16
EP2086981A1 (en) 2009-08-12
US9765076B2 (en) 2017-09-19
MX348568B (es) 2017-06-20
ZA200903279B (en) 2010-07-28
MY153243A (en) 2015-01-29
AU2007322046A1 (en) 2008-05-29
ES2528793T3 (es) 2015-02-12
US20080167292A1 (en) 2008-07-10
US20240400567A1 (en) 2024-12-05
CY1112828T1 (el) 2016-02-10
BRPI0718803B1 (pt) 2020-11-17
NO343338B1 (no) 2019-02-04
US10836766B2 (en) 2020-11-17
HRP20150047T1 (en) 2015-03-13
US20190031662A1 (en) 2019-01-31
UA94129C2 (ru) 2011-04-11
CN103483343B (zh) 2016-06-01
HK1175778A1 (en) 2013-07-12
JP2010510215A (ja) 2010-04-02
HRP20120490T1 (hr) 2012-07-31
US20110312942A1 (en) 2011-12-22
JP5452811B2 (ja) 2014-03-26
US9988384B2 (en) 2018-06-05
EP2497772B1 (en) 2014-10-29
ES2537451T3 (es) 2015-06-08
EP2497773A1 (en) 2012-09-12
EP2086981B1 (en) 2012-05-02
PH12012502057A1 (en) 2015-09-14
IL198690A0 (en) 2010-02-17
JP2014055166A (ja) 2014-03-27
ES2384123T3 (es) 2012-06-29
PL2086981T3 (pl) 2012-09-28
EP2497773B1 (en) 2015-02-25
DK2086981T3 (da) 2012-08-06
RS52313B (sr) 2012-12-31
AR064246A1 (es) 2009-03-25
US20110312943A1 (en) 2011-12-22
KR20090091173A (ko) 2009-08-26
JP5102839B2 (ja) 2012-12-19
EP2944639B1 (en) 2017-01-04
PT2497772E (pt) 2015-02-05
JP2012006965A (ja) 2012-01-12
SI2497772T1 (sl) 2015-03-31
KR101110458B1 (ko) 2012-03-13
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
MA30988B1 (fr) 2009-12-01
WO2008063525A1 (en) 2008-05-29
KR101342014B1 (ko) 2013-12-19
SG10201503350TA (en) 2015-06-29
HK1175777A1 (en) 2013-07-12
CR20140544A (es) 2015-01-12
CN103483343A (zh) 2014-01-01
GEP20125459B (en) 2012-03-26
EA200970486A1 (ru) 2009-10-30
CN101547924B (zh) 2013-09-25
SG176443A1 (en) 2011-12-29
CR20140154A (es) 2014-07-23

Similar Documents

Publication Publication Date Title
MX2009002121A (es) Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
IL196894A0 (en) Process for preparing 3-dihalomethylpyrazole-4-carboxylic acid derivatives
IN2012DN00606A (enExample)
GB0418900D0 (en) Novel salt forms
NZ599306A (en) Process for the preparation of compounds useful as inhibitors of sglt2
SG165380A1 (en) Process for the production of amides
UA102817C2 (ru) Способ синтеза агомелатина
IN2014CN00613A (enExample)
PE20100715A1 (es) Proceso para la sintesis de 5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-bencenamina
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
IL195187A0 (en) Process for production of radioactive fluorine-labeled organic compound
SG170794A1 (en) Process for preparation of hiv protease inhibitors
MX2011011025A (es) Preparacion de c-piracin-metilaminas.
WO2008077035A3 (en) Processes for the preparation of levetiracetam
WO2009072501A1 (ja) カーボネート化合物の製造方法
EA200900008A1 (ru) Новые хиральные промежуточные продукты, способ их получения и их применение в производстве толтеродина, фезотеродина или их активных метаболитов
IL200323A0 (en) Synthesis of glyt-1 inhibitors
IL183739A0 (en) Process for preparation of high-purity meloxicam and meloxicam potassium salt
TW200738621A (en) Chemical process
NZ589867A (en) Process for the synthesis of n-demethylated morphinane compounds
IL186979A0 (en) A process for the preparation of pyridine-methylsulfinyl compounds
MXPA05013604A (es) Procedimiento para preparar acilsulfamoilbenzamidas.
TW200602331A (en) Process for preparing thiazole compound
UA93860C2 (ru) Способ получения пиразолов, способ региоселективного алкилирования и применение фосфата или фосфоната b способе
MXPA05003695A (es) Nuevo proceso para la sintesis de compuestos de 1,3-dihidro-2h-3-benzazepin-2-ona, y aplicacion en la sintesis de ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 14 NOV 2017 BY COMPUTER PACKAGES INC

Effective date: 20150501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2018 BY COMPUTER PACKAGES INC

Effective date: 20171018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2019 BY COMPUTER PACKAGES INC

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2020 BY COMPUTER PACKAGES INC

Effective date: 20191018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2021 BY COMPUTER PACKAGES INC

Effective date: 20201020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2022 BY COMPUTER PACKAGES INC

Effective date: 20211017

LAPS Patent lapsed